Received for publication February 22, 2006.
Revised May 9, 2006.
Accepted for publication May 9, 2006.

Identification of Novel Small Molecule Inhibitors of APP Protein Synthesis as a Route to Lower Alzheimer's disease Amyloid- peptide

Abstract

A wealth of independent research with transgenic mice, antibodies and vaccines has pointed to a causative role of the amyloid- peptide (A) in Alzheimer's disease (AD). Based on these and earlier associative studies, A represents a promising target for development of therapeutics focused on AD disease progression. Interestingly, a cholinesterase inhibitor currently in clinical trials, phenserine, has been shown to inhibit production of both amyloid precursor protein (APP) and A. We have shown that this inhibition occurs at the post-transcriptional level with a specific blocking of the synthesis of APP relative to total protein synthesis (Shaw et al., 1999). However, the dose of phenserine necessary to block APP production is far higher than that needed to elicit its anticholinesterase activity and it is these latter actions that are dose limiting in vivo. The focus of this study was to screen 144 analogues of phenserine to identify additional small molecules that inhibit APP protein synthesis and, thereby, A production, without possessing potent acetylcholinesterase (AChE) inhibitory activity. An ELISA assay was used to identify analogues capable of suppressing APP production following treatment of human neuroblastoma cells with 20 µM of compound. Eight analogues were capable of dose-dependently reducing APP and A production without causing cell toxicity in further studies. Several of these had little to no AChE activities. Translation of APP and A actions to mice was demonstrated with one agent. They thus represent interesting lead molecules for assessment in animal models, to define their tolerance and utility as potential AD therapeutics.

Key words: APP, Alzheimer's disease, amyloid, post-transcriptional, therapeutics, translation

This article has been cited by other articles:

				A. Marutle, M. Ohmitsu, M. Nilbratt, N. H. Greig, A. Nordberg, and K. Sugaya Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine PNAS, July 24, 2007; 104(30): 12506 - 12511. [Abstract] [Full Text] [PDF]

				D. K. Lahiri, D. Chen, B. Maloney, H. W. Holloway, Q.-s. Yu, T. Utsuki, T. Giordano, K. Sambamurti, and N. H. Greig The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 386 - 396. [Abstract] [Full Text] [PDF]